South Dakota Investment Council lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 27.4% in the third quarter, Holdings Channel.com reports. The fund owned 120,934 shares of the company’s stock after selling 45,731 shares during the quarter. South Dakota Investment Council’s holdings in Merck & Co., Inc. were worth $17,573,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the business. Bullseye Investment Management LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter worth $27,000. Curry Webb Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the third quarter valued at $29,000. Horizons Wealth Management bought a new position in shares of Merck & Co., Inc. in the third quarter worth about $30,000. Graney & King LLC grew its holdings in shares of Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC bought a new position in shares of Merck & Co., Inc. in the second quarter worth about $41,000. Institutional investors own 76.07% of the company’s stock.
Insider Buying and Selling at Merck & Co., Inc.
In related news, EVP Richard Deluca sold 58,185 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $148.01, for a total value of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares of the company’s stock, valued at $16,718,469.55. This represents a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is owned by insiders.
Merck & Co., Inc. Trading Down 1.0%
Shares of NYSE MRK opened at $143.01 on Wednesday. Merck & Co., Inc. has a twelve month low of $92.11 and a twelve month high of $156.92. The firm has a market cap of $352.56 billion, a PE ratio of 147.43, a price-to-earnings-growth ratio of 6.62 and a beta of 0.13. The business has a fifty day simple moving average of $145.93 and a two-hundred day simple moving average of $128.97. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the prior year, the company earned $2.58 EPS. The business’s revenue was up 4.7% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.
Merck & Co., Inc. Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, December 15th. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85. This represents a $3.52 annualized dividend and a dividend yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio is presently 350.52%.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on the stock. DZ Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and set a $153.00 price target on the stock. in a research note on Tuesday, November 3rd. Jefferies Financial Group boosted their price objective on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Cantor Fitzgerald boosted their price objective on shares of Merck & Co., Inc. from $145.00 to $155.00 and gave the company a “neutral” rating in a research report on Monday, November 2nd. Zacks Research downgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Monday, October 19th. Finally, HSBC raised their target price on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $155.74.
View Our Latest Report on Merck & Co., Inc.
Key Merck & Co., Inc. News
Investors following MRK have been watching these news items:
- Positive Sentiment: Merck has reported recent pipeline progress, including positive European committee opinions on expanded indications for ENFLONSIA and WELIREG, as well as Phase 2b results for liver-disease candidate efinopegdutide. These developments support its effort to broaden growth beyond KEYTRUDA. Read More.
- Positive Sentiment: Goldman Sachs raised its price target to $165 from $155 and maintained a Buy rating, signaling continued analyst optimism. Read More.
- Neutral Sentiment: Merck announced a first-quarter 2027 dividend; the provided report did not specify the amount. Read More.
Merck & Co., Inc. Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
